Apcegen is ready to start non-clinical studies of its first alternate therapy biologic targeted against Rheumatoid Arthritis.

Apcegen Technologies has announced today that they are soon starting non-clinical trials of their first alternate therapy biologic drug candidate (ATAF11).

Bengaluru, Karnataka, March 17, 2015 /India PRwire/ -- Apcegen Technologies has announced today that they are soon starting non-clinical trials of their first alternate therapy biologic drug candidate (ATAF11). The ATAF11 is a first of its kind of product to be available in India and is a much safer alternative to the current biologics/biosimilars available in India. The ATAF11 is an anti TNF alfa biologic drug candidate developed to treat Rheumatoid Arthritis, Crohn's disease and other TNF related auto immune disorders. ATAF11 is an indegeniously developed product and is been funded by Dapartment of Biotechnology.

Journalists and Bloggers
Visit India PRwire for Journalists for releases, photos, email alerts and customized feeds just for Media.

If you have any query regarding information in the press releases, please contact the company listed in the press release itself. Please do not call India PRwire, we will be unable to assist you with your inquiry.


Apcegen Technologies recent press release(s)


Apcegen Technologies secures NSTEDB and TePP funding's from DST

Apcegen Technologies, a start-up Biopharma development company has announced today that Apcegen has secured seed support under NSTEDB and TePP schemes from Department of Science and Technology (DST) for the development of two of it's Biobetters.